Moomoo AI 已提取核心信息
Cassava Sciences, Inc., a biopharmaceutical company, has announced the issuance of warrants to purchase additional shares of its common stock. The distribution of these warrants, referred to as the Warrant Distribution, was declared by the company's Board of Directors and is scheduled for January 3, 2024, to shareholders of record as of December 22, 2023. Each warrant allows the holder to buy one share of common stock at an exercise price of $33.00, along with a Bonus Share Fraction of 0.5 of a share, under certain conditions. The Bonus Share Fraction is available until a specified expiration date, which is determined by either a 30-day trading period price condition or a date set by the company with a minimum of 20 business days' notice. The warrants...Show More
Cassava Sciences, Inc., a biopharmaceutical company, has announced the issuance of warrants to purchase additional shares of its common stock. The distribution of these warrants, referred to as the Warrant Distribution, was declared by the company's Board of Directors and is scheduled for January 3, 2024, to shareholders of record as of December 22, 2023. Each warrant allows the holder to buy one share of common stock at an exercise price of $33.00, along with a Bonus Share Fraction of 0.5 of a share, under certain conditions. The Bonus Share Fraction is available until a specified expiration date, which is determined by either a 30-day trading period price condition or a date set by the company with a minimum of 20 business days' notice. The warrants, which are redeemable by the company starting April 15, 2024, will expire on November 15, 2024, if not exercised. They are expected to begin trading on the Nasdaq Capital Market under the ticker 'SAVAW' from January 4, 2024. The company has filed a prospectus supplement for the registration of the shares associated with the warrants under its existing shelf registration statement. This move is part of Cassava Sciences' strategic financial activities and does not constitute an offer to sell or a solicitation of an offer to buy the securities.
生物制药公司Cassava Sciences, Inc. 宣布发行认股权证，以购买其普通股的额外股份。这些认股权证（称为认股权证分配）由公司董事会宣布，计划于2024年1月3日分发给截至2023年12月22日的登记股东。在某些条件下，每份认股权证允许持有人以33.00美元的行使价购买一股普通股，并获得每股0.5％的红股分数。奖励股份分数在指定的到期日之前有效，该到期日由30天交易期价格条件决定，或者由公司设定的至少提前20个工作日发出通知的日期决定。认股权证自2024年4月15日起可由公司兑换，如果不行使，将于2024年11月15日到期。预计它们将从2024年1月4日起在纳斯达克资本市场开始交易，股票代码为 “SAVAW”。该公司已根据其现有的上架注册声明提交了与认股权证相关的股份注册的招股说明书补充文件。此举是Cassava Sciences战略财务活动的一部分，不构成卖出要约或收购证券要约的邀请。
生物制药公司Cassava Sciences, Inc. 宣布发行认股权证，以购买其普通股的额外股份。这些认股权证（称为认股权证分配）由公司董事会宣布，计划于2024年1月3日分发给截至2023年12月22日的登记股东。在某些条件下，每份认股权证允许持有人以33.00美元的行使价购买一股普通股，并获得每股0.5％的红股分数。奖励股份分数在指定的到期日之前有效，该到期日由30天交易期价格条件决定，或者由公司设定的至少提前20个工作日发出通知的日期决定。认股权证自2024年4月15日起可由公司兑换，如果不行使，将于2024年11月15日到期。预计它们将从2024年1月4日起在纳斯达克资本市场开始交易，股票代码为 “SAVAW”。该公司已根据其现有的上架注册声明提交了与认股权证相关的股份注册的招股说明书补充文件。此举是Cassava Sciences战略财务活动的一部分，不构成卖出要约或收购证券要约的邀请。
有用
没用